In the end, these data suggest that combinations of platinum drugs with C-KIT, MAPK, PI3K or PARP inhibitors may be a suitable therapy to avoid recidiva or metastasis in ovarian tumors or for the treatment of platinum-resistant tumors. The gene discussed is KIT; the disease is ovarian neoplasm.